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Abstract
Background and hypothesis: Heterogeneity in clinical manifestations and disease progression in Chronic Obstructive
Pulmonary Disease (COPD) lead to consequences for patient health risk assessment, stratification and management.
Implicit with the classical “spill over” hypothesis is that COPD heterogeneity is driven by the pulmonary events of the
disease. Alternatively, we hypothesized that COPD heterogeneities result from the interplay of mechanisms governing
three conceptually different phenomena: 1) pulmonary disease, 2) systemic effects of COPD and 3) co-morbidity
clustering, each of them with their own dynamics.
Objective and method: To explore the potential of a systems analysis of COPD heterogeneity focused on skeletal
muscle dysfunction and on co-morbidity clustering aiming at generating predictive modeling with impact on
patient management. To this end, strategies combining deterministic modeling and network medicine analyses of
the Biobridge dataset were used to investigate the mechanisms of skeletal muscle dysfunction. An independent
data driven analysis of co-morbidity clustering examining associated genes and pathways was performed using a
large dataset (ICD9-CM data from Medicare, 13 million people). Finally, a targeted network analysis using the
outcomes of the two approaches (skeletal muscle dysfunction and co-morbidity clustering) explored shared
pathways between these phenomena.
Results: (1) Evidence of abnormal regulation of skeletal muscle bioenergetics and skeletal muscle remodeling showing
a significant association with nitroso-redox disequilibrium was observed in COPD; (2) COPD patients presented higher
risk for co-morbidity clustering than non-COPD patients increasing with ageing; and, (3) the on-going targeted network
analyses suggests shared pathways between skeletal muscle dysfunction and co-morbidity clustering.
Conclusions: The results indicate the high potential of a systems approach to address COPD heterogeneity.
Significant knowledge gaps were identified that are relevant to shape strategies aiming at fostering 4P Medicine
for patients with COPD.
Introduction
COPD is a highly heterogeneous major chronic disease
Chronic Obstructive Pulmonary Disease (COPD) is a
prevalent chronic disorder caused by the inhalation of
irritants, mainly tobacco smoke. It affects approximately
9% of the adult population above 45 yrs [1]. The disease
imposes a high burden on healthcare systems worldwide
and it is currently the fourth leading cause of mortality
[2]. In 2001, the World Health Organization (WHO)
included COPD among the five major chronic disorders
together with cardiovascular diseases, cancer, diabetes
and mental disorders [3].
Current diagnosis of COPD is based on three concur-
rent criteria [4]: i) presence of respiratory symptoms,
mainly shortness of breath and/or chronic cough/spu-
tum; ii) history of inhalation of irritants; and, iii) forced
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spirometry testing indicating an obstructive ventilatory
defect. The expiratory flow limitation observed in
COPD patients is due to increased airways resistance
and/or reduced lung elasticity caused by destruction of
pulmonary parenchyma.
Approximately 15 to 20% of all tobacco smokers are
prone to develop COPD and there is marked individual
variability of both clinical manifestations and pulmonary
disease progression [5-7] with relevant implications in
terms of health risk assessment and patient management
[6,8]. It is well established that COPD patients can present
acute episodes of exacerbation with a negative impact on
use of healthcare resources and prognosis [6,9]. Moreover,
these patients can also show systemic effects of the disease
- being skeletal muscle dysfunction/wasting [10] a charac-
teristic one - and co-morbid conditions [6,11]. Highly pre-
valent chronic conditions such as cardiovascular disorders
(CVD) and type 2 diabetes mellitus - metabolic syndrome
(T2DM-MS) are often present as a co-morbidity cluster in
COPD patients [12-14]. There is evidence that both skele-
tal muscle dysfunction/wasting and co-morbidity clustering
are independently associated with poor prognosis [1,6,10].
State of the art on COPD heterogeneity and main
challenges
The Global initiative for Obstructive Lung Disease
(GOLD) [1] has played a major role in raising COPD
awareness and defining standards for treatment. GOLD
has faced the challenge of COPD heterogeneity by evol-
ving from an initial disease staging based only on the
degree of airflow limitation (FEV1, forced expiratory
volume during the first second) [15] to the incorporation
of symptoms and frequency of severe exacerbations into
the scoring system (2011 GOLD update) (see Table 1 for
details) and acknowledging the negative impact of co-mor-
bid conditions on prognosis. Evidence-based data using
the 2011 GOLD classification are currently emerging, but
the results are not yet consolidated [16,17]. Alternative
available options for COPD classification or prediction of
survival [18-22] are also insufficient for subject-specific
prediction and stratification of management.
ECLIPSE - The Evaluation of COPD Longitudinally to
Identify Predictive Surrogate End-points study - has
been a 3-year follow-up project of a large cohort of well
characterized COPD GOLD II-IV patients [23] that has
generated a relevant body of knowledge on several
major aspects of the disease. A recent summary report
(2014) on clinical implications of the project outcomes
[6] stresses the impact of COPD heterogeneity observed
in both the cross-sectional and the longitudinal study
assessments.
All in all, there is a strong rationale for further research
on subject-specific health risk prediction and stratification
aiming at enhancing cost-effective management of COPD
patients. However, there are several major challenges to be
taken into account in the design of a systems approach to
better understand COPD heterogeneity. Firstly, the overlap
among different chronic obstructive airways diseases
(COPD, asthma, bronchiectasis, bronchiolitis, etc...)
requires novel disease taxonomies based on a better
knowledge of underlying mechanisms that may likely
result in a re-definition of COPD as a pulmonary disease
[24]. Such an approach should solve three current deficits,
namely: i) overlap between COPD and lung ageing; ii)
availability of operational diagnostic criteria differentiating
COPD from other obstructive pulmonary diseases; and,
iii) a proper capture of pulmonary heterogeneity of the
disease. Another major challenge is to clarify the current
confusion between systemic effects of COPD and some
co-morbid conditions due to the descriptive nature of the
reporting. As an example, is anxiety-depression a systemic
effect ?, a COPD complication? or a co-morbid condition?.
Likely, a proper understanding of the mechanisms
involved in the relationships between systemic inflamma-
tion in COPD and depression [25,26] may help to clarify
this type of questions. To prevent further confusion,
Synergy-COPD was focused on the analysis of skeletal
muscle dysfunction/wasting as a well accepted paradigm
of a systemic effect of COPD. Last, but not least, a major
challenge is a proper understanding of the phenomenon of
co-morbidity clustering. There is evidence indicating that
co-morbidity clustering is only partly explained by shared


















mMRC 0-1 mMRC ≥ 2
CAT < 10 CAT ≥ 10
The 2011 COPD Update [1] defines four risk categories for COPD patients (A to D) depending upon: i) symptoms (modified dyspnea score from th Medical
Research Council, mMRC) or CAT questionnaire; ii) spirometric classification: GOLD I: FEV1 ≥ 80% pred; GOLD II: 50% ≤ FEV1 < 80% pred; GOLD III: 30% ≤ FEV1 <
50% pred; and, GOLD IV: FEV1 < 30% and/or PaO2 < 60 mmHg breathing FIO2 0.21); and, iii) frequency of exacerbations per year. Recent reports have assessed
the predictive value of this classification [16,17]
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risk factors among the concurrent diseases [12,27,28],
namely: tobacco smoking, unhealthy diet and sedentarism.
The Synergy-COPD project
As stated in [29] of the current Supplement, the Synergy-
COPD project was conceived as a systems approach to
explore the role of combined modeling strategies to better
understand COPD heterogeneity. Within the core aim of
the project was the purpose of transferring the acquired
knowledge into healthcare by designing innovative strate-
gies to effectively build-up 4P Medicine: predictive, pre-
ventive, personalized and participatory medicine for
chronic patients. In this regard, COPD was identified as a
proper use case to explore the potential for generalization
of the approach to other chronic conditions.
The current chapter focuses on the biomedical dimen-
sions of the project taking into consideration the implica-
tions on the healthcare scenario. Figure 1 depicts relevant
bio-pathological processes involved in COPD displayed
according to the classical “spill over” hypothesis [30] to
explain the systemic effects of the disease. Two main lim-
itations of this hypothesis are; i) its over-simplistic expla-
nation of the phenomenon of systemic low-grade
inflammation, not confirmed by ECLIPSE [6,11] and other
studies [28] and, ii) lack of a proper consideration of the
co-morbidity challenge. An implicit assumption of the
hypothesis is that COPD heterogeneity is ultimately driven
by the pulmonary events of the disease.
Alternatively, Synergy-COPD proposed that COPD het-
erogeneity is explained by the interplay of conceptually
independent events occurring at three different levels: i)
Pulmonary disease - determined by the effects of lung
injury and local remodeling processes; ii) Systemic effects
of the disease with different manifestations, such as skele-
tal muscle dysfunction/wasting [10]; and, iii) Co-morbid-
ity clustering that refers to observed associations of
different chronic disorders. Synergy-COPD targeted the
analysis of associations among CVD, T2DM-MS and
COPD. The project explored underlying mechanisms of
COPD heterogeneity focusing on skeletal muscle dysfunc-
tion/wasting and co-morbidity clustering and it only mar-
ginally addressed pulmonary events of the disease.
Method
Planned strategies for assessing COPD heterogeneities
The overall biomedical strategy of the project and the
specific input datasets have been reported in detail in
[29]. Moreover, the different modeling tools and strate-
gies are described in [31]. The three biomedical areas
addressed in Synergy-COPD had specific study designs
that are summarized below:
Skeletal muscle dysfunction - The project explored
three relevant aspects of skeletal muscle dysfunction and
muscle wasting in COPD patients. Firstly, Synergy-COPD
examined the degree of association between classical
COPD GOLD stages (I to IV) and estimations of both
Figure 1 Lung injury caused by inhaled irritants like tobacco smoking generates peripheral lung inflammation that may cause “spill
over” of different types of cytokines into the systemic circulation. According to this hypothesis, systemic inflammation causes skeletal
muscle dysfunction and muscle wasting, but it may also cause and worsen co-morbidities (reproduced from [30]with permission)
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cellular oxygenation (PmO2) and mitochondrial reactive
oxygen species (ROS) levels in skeletal muscle exercising
maximally (VO2max). The study was done using a COPD
dataset wherein VO2max, cardiac output (QT), pulmonary
ventilation-perfusion mismatching (VA/Q inequalities) and
blood oxygenation, arterial and mixed venous blood, had
been measured [32]. The analysis was carried out using the
integrated deterministic model developed in the project
wherein an integrated physiological O2 pathway model was
made interoperable with a biochemical model characteriz-
ing mitochondrial ROS generation, as reported in detail in
[31]. Likewise, such an analysis was also done using the Bio-
bridge dataset [33] wherein healthy subjects and COPD
patients had a multilevel (omics, biochemical, physiological
and clinical data) characterization of lower limb muscle,
blood and whole-body changes from pre- to post- high
intensity supervised resistance training during 8 weeks.
A second study in the project enriched the initial net-
work medicine analysis [34-36]) from the Biobridge data-
set [33] by including additional “omics” information
[27,28], as well as an extended set of measurements on
nitroso-redox balance carried out in blood and in skeletal
muscle [28]. The purpose of the network approach
described in detail in [31] was to compare healthy sub-
jects and COPD patients in terms of the relationships
among relevant metabolic pathways governing cellular
bioenergetics, protein balance, and skeletal muscle remo-
deling paying particular attention to the role of nitroso-
redox disequilibrium in the network modeling.
Finally, a third study undertaken within Synergy-COPD
addressed the analysis of abnormal training adaptations
comparing healthy subjects and COPD from the Biobridge
database. Two different modeling strategies were underta-
ken: targeted probabilistic network modeling [34,37,38]
and a Thomas network approach, as described in detail in
[31]. In the former, associations between estimated skele-
tal muscle ROS levels obtained with the integrated deter-
ministic model were compared with actual measurements
pre- and post-training carried out both in blood and ske-
letal muscle.
Co-morbidity analyses - Two different studies were
undertaken. Firstly, a data driven approach aimed at asses-
sing different indices of relative risk for co-morbidity clus-
tering in COPD patients aged +65 yrs compared to non-
COPD patients. As reported in [29], the study was done
using the Medicare dataset (13 million people) [29,31].
The research also identified genes and pathways associated
with clusters of co-morbidities. A second independent
study compared the outcomes of the data driven study
with the pathway analysis of the co-morbidity clustering
targeted in Synergy-COPD, namely: CVD, T2DM-MS and
COPD as reported in [12,13]. The relevant pathways iden-
tified in the analysis of skeletal muscle dysfunction/wasting
were compared with those seen in the co-morbidity clus-
tering to explore commonalities.
Pulmonary events - In 2011, the PAC_COPD study [39]
reported an unbiased cluster analysis identifying subtypes
of COPD patients with clinical and prognostic implications.
In the study [39], there was evidence of a dissociation
between relatively low central airways resistance and high
emphysema score in approximately one third of the
patients. Because of the potential interest of the finding in
terms of patient stratification, we used modeling techniques
exploring spatial pulmonary heterogeneities to address the
issue, as described in detail in [40]. The study was done in
close collaboration with the AIRPROM project.
Health risk assessment and patient stratification
The design of strategies aiming at speeding the transfer of
biomedical research achievements into clinical practice
constitutes a core objective of Synergy-COPD. To this
end, three specific goals were identified: i) to better under-
stand the underlying biological mechanisms of the phe-
nomena indicated above, namely: skeletal muscle
dysfunction, co-morbidity clustering and dissociation
between airway remodeling and emphysema score in
COPD patients; ii) to identify combined markers with
potential predictive power; and, iii) to construct patient-
specific predictive modeling useful for the clinical decision
making processes in primary care. The project outcomes
from these three areas should help to generate rules feed-
ing Clinical Decision Support Systems (CDSS) embedded
into the clinical processes in primary care. The CDSS pro-
duced in the project targeted the areas displayed in Table
2. They were embedded into clinical processes supported
by the Integrated Care Shared Knowledge Platform [41]
deployed in the integrated healthcare district of Barcelona-
Esquerra. Specific validation strategies were defined and
executed, as reported in detail in [42].
Results
Contributions to knowledge on COPD heterogeneities
Figure 2 summarizes four major aspects of the Synergy-
COPD project: (i) main input data for the analyses, also
described in detail in [29] and [43]; (ii) main biomedical
analyses carried out during the project lifetime; (iii) novel
resources generated from the developments done; and,
finally, (iv) areas of impact from the project and recom-
mendations to be done beyond the project life span.
Skeletal muscle dysfunction in COPD patients.
Figure 3 displays the relationships between estimated
skeletal muscle PO2 (PmO2) and mitochondrial ROS
production for different levels of maximum O2 transport
and mitochondrial utilization capacity in a group of
COPD patients with mild to severe disease [32], as
explained in the figure legend. The central messages of
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this analysis were: i) PmO2 at maximal exercise is deter-
mined by the ratio between O2 transport to mitochon-
drial and O2 utilization capacity (VO2max/Vmax ratio),
such that the lower the maximum O2 transport poten-
tial for a given mitochondrial capacity, the lower PmO2;
ii) tissue oxygenation levels were not related with
GOLD stages; and, iii) low PmO2 values associated with
abnormally high mitochondrial ROS production at peak
exercise were predicted to occur in these patients. The
analysis of the relative impact of the determinants of
skeletal muscle oxygenation using the integrated model
of O2 pathway and mitochondrial ROS generation also
indicated: (1) how functional heterogeneities of skeletal
muscle VO2max/Vmax ratios may generate both very
low and very high PmO2 in the skeleletal muscle of
these patients; and (2) the high impact of lung heteroge-
neity decreasing overall O2 transport, as compared with
the rather moderate role of skeletal muscle heterogene-
ity on mean PmO2.
The Biobridge dataset [27,28,33] clearly indicated that
COPD patients at rest, before training, showed nitroso-
redox disequilibrium both in blood and skeletal muscle
compared to healthy controls (Figure 4, upper panel).
Moreover, a significant association of protein carbonyla-
tion levels between blood and skeletal muscle was
observed in the patients (Figure 4, bottom panel) [28] in
whom low-grade inflammation in peripheral blood, but
not in skeletal muscle, was observed. The plasma
Figure 2 Diagram indicating input data (top rectangles with discontinuous line), biomedical achievements (central grey rectangles),
resources generated by the project (bottom rectangles with continuous line) and further developments to be considered after the
Synergy-COPD project. (blue rectangles).
Table 2 Clinical Decision Support Systems (CDSS) developed in Synergy-COPD for COPD management in an integrated
care scenario.
1. Early diagnosis - COPD case finding program The suite of CDSS supports the regional deployment of a program of early COPD
diagnosis targeting citizens at risk examined in pharmacy offices and non-diagnosed patients studied in primary care. Additional
objectives of the program are to ensure high quality forced spirometry accessible across heathcare tiers, as well as prevention of over-
diagnosis of COPD in elderly due to the GOLD diagnostic criteria [1].
2. Enhanced stratification of COPD patients It includes three families of CDSS with well differentiated objectives: i) enhance applicability
of the 2011 GOLD Update criteria for COPD staging [1]; ii) facilitate off-line comparisons with other COPD staging criteria, namely: BODE,
DOSE, ADO, etc...[18-21]; and, iii) enhanced stratification combining acquired knowledge in Synergy-COPD and consolidated findings from
ECLIPSE [6].
3. Community-based integrated care program The suite of CDSS aims at supporting different integrated care services fostering the
transfer of complexity from specialized care to the community with an active role of patients. The two programs being deployed are: i)
sustainability of training-induced effects and promotion of physical activity; and, ii) management of patients under long-term oxygen
therapy (LTOT). The two programs were assessed within NEXES [41,49], as part of the deployment of integrated care services in the
health district of Hospital Clinic.
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metabolomic analysis in COPD was fully consistent with
abnormal skeletal muscle abnormalities reported in
these patients [27], namely: decreased oxidative capacity
leading to abnormal ROS generation [28,44,45], up-reg-
ulation of glycolysis [46] and altered aminoacid metabo-
lism [27,46] (Figure 5). The transcriptomic analysis
showed lower and abnormal skeletal muscle gene
expression at baseline in COPD patients compared to
healthy subjects with clear differences between COPD
patients with preserved skeletal muscle mass and those
showing muscle wasting [33].
Most importantly, the network medicine approach
assessing associations among three major pathways,
namely bioenergetics, inflammation and skeletal muscle
remodeling showed clear differences between the probabil-
istic models obtained in healthy subjects and those seen in
COPD patients indicating failure to coordinately activate
these pivotal metabolic pathways in the patients (Figure 6).
Moreover, a sub-analysis carried out with few muscle sam-
ples identified a potential role of epigenetic changes con-
tributing to the phenomenon of abnormal regulation of
key metabolic pathways seen in COPD patients.
The study [27,28] demonstrated that high intensity 8-
w endurance training significantly enhanced aerobic
capacity both in healthy controls and in COPD patients
without harmful effects on nitroso-redox equilibrium in
severe COPD patients, but it confirmed abnormal train-
ing-induced skeletal muscle adaptations of the redox
system in COPD indicated by a poor post-training
increase of total gluthatione to oxidized gluthatione
ratio in skeletal muscle seen in healthy subjects. On-
going network analyses using the Biobridge dataset
[27,28,33] further supports a pivotal role of nitroso-
redox disequilibrium on skeletal muscle dysfunction in
COPD patients.
Figure 3 Relationships between measured maximum O2
transport (VO2), y-axis; and, estimated cellular oxygenation
(PmO2), x-axis, in COPD patients. The different symbols
correspond to classical GOLD stages: squares, GOLD II; circles GOLD
III; and, triangles, GOLD IV (measured VO2 obtained from [32]). The
symbols connected with discontinuous lines correspond to the
same patient (same VO2) with estimated PmO2 values
corresponding to different mitochondrial oxidative capacities (Vmax
values and VO2/Vmax ratios). For a given patient, the lower the VO2/
Vmax ratio, the lower was the estimated PmO2. The colors
correspond to the mitochondrial ROS generation: green,
mitochondrial ROS levels similar to those seen in healthy subjects;
red, abnormally high mitochondrial ROS levels; and, violet, high ROS
levels that persist after exercise withdrawal. The lower the PmO2,
the higher were mitochondrial ROS levels.
Figure 4 Oxidative stress in COPD. Upper panel: Muscle
oxidative stress. Individual and mean group effects of an 8-week
endurance training program on protein carbonylation (left) and
protein nitration (right) in the vastus lateralis of healthy subjects
(controls) and patients with COPD. At baseline (rest, pre-training
measurements), COPD patients showed higher nitroso-redox
disequilibrium than healthy subjects. A trend toward a decrease in
oxidative stress was observed after training in COPD patients [28].
Bottom panel: Association between muscle and blood. COPD
patients at baseline (rest, pre-training) showed an association of
protein carbonylation levels between skeletal muscle and blood [28]
(reproduced from[28]with permission).
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Co-morbidity clustering - The large data driven ana-
lysis of co-morbidities indicated that COPD patients
showed a higher risk for co-morbidity clustering than
non-COPD patients of the same age. Not surprisingly,
the likelihood for co-morbidity occurrence in COPD
patients significantly increased with age for most condi-
tions. Moreover, it was shown that specific cytokines
and variables associated to the redox system [28,46] pre-
sented significant relationships with co-morbidity clus-
tering in COPD patients. The network medicine analysis
of the targeted co-morbidity clustering including CVD
and T2D-MS is currently underway.
Dissociation between airway remodeling and pul-
monary emphysema - The modeling of spatial pulmonary
heterogeneities was used to explore the characteristics of
patients from the PAC-COPD study [39] in whom moder-
ate to severe emphysema score, assessed by high resolu-
tion CT scan, was not accompanied by significant central
airway remodeling. Consequently, these COPD patients
showed mild FEV1 impairment. Unfortunately, the matur-
ity of the modeling developments did not allow comple-
tion of the analysis as initially planned, see [40] for further
details.
Tackling COPD heterogeneities to enhance health
outcomes
As part of the strategies for transferring novel biomedical
knowledge into the clinical arena, we developed three
families of CDSS (Table 2) that were embedded into the
clinical processes at primary care level using an Integrated
Care Shared Knowledge Platform [41] as technological
support to facilitate the management of chronic patients.
The CDSS’ rules combined existing and novel knowledge
generated during the project’s life-span, as explained in
detail in [42]. The CDSS areas addressed in the project are
briefly described below:
Early diagnosis of COPD - A COPD case-finding pro-
gram for citizens with high risk for developing COPD was
deployed at local level [41]. The program encompasses dif-
ferent aspects: i) remote support to automatic assessment
of quality of forced spirometry both in pharmacy offices
and primary care [47]; ii) support to coordination between
informal care (pharmacy offices) and formal care (primary
care and specialists); and, iii) enhanced 2011 GOLD-based
COPD assessment with the use of recommended reference
equations [48].
Enhanced stratification of COPD patients. A suite of
CDSS supporting proposals for patient stratification has
been built-up. The CDSS facilitates comparisons with
available predictive indices for COPD patients. That is,
classical GOLD staging (groups 1 to 4 based on FEV1 %
predicted) and 2011 GOLD update (groups A to D), taking
into account symptoms score and frequency of severe
exacerbations, can be automatically constructed and dis-
played in the primary care clinical workstation. Co-mor-
bidities expressed as number&type and Charlson index are
also considered together with novel proposals for decision
algorithms based on the Synergy-COPD findings, as
detailed in [42].
Community-based integrated care management of
COPD patients. Deployment experiences of integrated
care services [41] developed in parallel with Synergy-
COPD have demonstrated positive health outcomes
together with cost-containment through the transfer of
healthcare complexity from specialized care to the com-
munity fostering an active and participatory role of both
citizens at risk, patients and carers. In this scenario, the
use of CDSS to support health professionals for chronic
Figure 5 Metabolic analysis. Upper panel: Resting individual
metabolic profiles in COPD patients (spheres) and in healthy
sedentary subjects (cubes), including pre (black symbols) - and post
-training data (grey symbols). The results are expressed by the three
Latent Variables (LV1, 2 and 3) of the partial-least square
discriminant analysis (PLS-DA). The percentages indicate the
magnitude of the differences between the two groups of subjects
for each dimension (p<0.05). Bottom panel: Endurance training
responses of individual metabolites. Mean training-induced
responses of individual metabolites. Data expressed as percent of
change are indicated as mean ± SEM. (*p<0.001; † p<0.01; ‡ p<0.05)
(reproduced from [27]with permission)
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care management appears as an effective approach to
transfer novel biomedical knowledge into healthcare.
Such an approach was assessed in the validation work
package of the project. Moreover, the parallel deploy-
ment experiences [41] carried out during the life time of
the project identified the high potential of the Personal
Health Folder (PHF) [49] for transferring different types
of non-medical patient information, namely: life-styles,
social frailty, adherence profile, etc... into formal health-
care, as detailed in [50].
Lessons learnt to foster 4P Medicine of chronic conditions
Synergy-COPD proposes a comprehensive strategy to fos-
ter the interplay between system research and predictive
medicine for chronic conditions. This purpose led to the
inception of the Digital Health Framework (DHF) exten-
sively presented in [50] of the current Supplement, as the
Synergy-COPD’s proposal to favor iterations between
informal care, formal care and biomedical research.
Discussion
Biomedical contributions to COPD heterogeneity
The overall biological findings generated by the different
studies associated with the project support the concept
that the pulmonary events of the disease are not the only
driver, and sometimes neither the main one, of the distur-
bances seen in these patients and do not explain by them-
selves COPD heterogeneity. Instead, a constellation of
concurrent factors (systemic effects of tobacco, lack of
physical activity, unhealthy diet, patient susceptibility
to oxidative stress, cellular hypoxia, etc...) may lead to sys-
temic nitroso-redox disequilibrium and low-grade blood
inflammation seen in COPD patients with skeletal muscle
dysfunction/wasting, as well as in those with co-morbidities.
There is evidence supporting that the combination of
the subject’s genetic susceptibility, changes in functional
genomics, partly regulated by epigenetic events, together
with changes in post-translational regulatory phenomena
at several levels may modulate the impact of the factors
triggering the disease and ultimately may determine the
clinical manifestations, as well as the rate of progression of
the different COPD components: pulmonary, systemic
effects and co-morbidity clustering. Moreover, it can be
speculated that the tight multilevel regulation of aerobic
capacity in man [26], may constitute a relevant factor
explaining the interdependence among the three drivers of
COPD heterogeneity. As a simplified example, down-regu-
lation of the skeletal muscle tricarboxilic acid cycle (TCA)
metabolism together with up-regulation of glycolysis have
been extensively reported in COPD patients with skeletal
muscle dysfunction [10] as a leading cause of early lactate
release during moderate exercise. The phenomenon over-
loads the ventilatory function facilitating air trapping and
shortness of breath often contributing to sedentarism
which, in turn, may constitute one of the contributing fac-
tors to insulin resistance, and T2DM, often seen in these
patients. Obviously, the progression of pulmonary disease
severity contributes to the vicious circle because it worsens
Figure 6 Interaction networks using skeletal muscle expression profiling, plasma cytokines and physiological measurements.
Uncoupling between bioenergetics, inflammation and skeletal muscle remodeling was observed in COPD patients as compared to healthy
subjects [33]
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the underlying mechanisms involved in the systemic
effects of COPD and the co-morbidity clustering.
The unifying hypothesis proposed by Synergy-COPD is
supported by all the findings observed in the different stu-
dies carried out in the project. Moreover, it is consistent
with different reports in the literature [26,44] indicating
that preserved aerobic function seems to be associated
with nitroso-redox equilibrium in the cardiovascular sys-
tem and, consequently, with O2 flow to O2 uptake match-
ing in peripheral tissues. All in all, the novel view of
COPD heterogeneity proposed by the Synergy-COPD pro-
ject has profound implications in terms of patient health
risk assessment and stratification, but most importantly, it
may deeply modulate both management and therapeutic
approaches of these patients.
The 2014 report [6] analyzing the clinical implications of
the ECLIPSE results strengthen the relevance of COPD
heterogeneity on the clinical management of these
patients. However, the highly valuable ECLIPSE’s achieve-
ments favoring a new clinical vision of COPD essentially
have a descriptive nature with well recognized limitations
in terms of generating evidence on novel underlying dis-
ease mechanisms.
In summary, there are three relevant lessons learnt
both from the project itself and from recent contribu-
tions like ECLIPSE:
• The characteristics of COPD heterogeneity clearly
generate a mandate for the design of strategies aiming
at individual health risk assessment and patient-
oriented management stratification aiming at setting
cost-effective preventive interventions to modulate dis-
ease progress.
• The unifying hypothesis for COPD heterogeneity
explored in Synergy-COPD contains the core ele-
ments for the design of a coherent patient stratifica-
tion strategy, as proposed in the current manuscript.
• The still on-going network analyses in Synergy-
COPD may generate “in silico” hypothesis on the
specifics of underlying mechanisms of COPD hetero-
geneity to be implemented in further refined ver-
sions of the proposed CDSS.
Modeling tools and strategies
The project has generated important modeling outcomes
and it has identified relevant challenges to be faced beyond
the project lifetime. Moreover, Synergy-COPD has also
shaped specific approaches to face those challenges, as
extensively discussed in [31]. We acknowledge, however,
limited achievements in terms of identification of com-
bined biomarkers with predictive power, as well as in the
development of subject-specific predictive modeling to
feed the CDSS for the reasons discussed in other areas of
the Supplement. We also recognized limited achievements
in the targeted objectives relative to pulmonary events.
There is no doubt that the positive interactions with AIR-
PROM will contribute to a maturity of the modeling of
pulmonary spatial heterogeneities described in [40] allow-
ing to further undertake this specific challenge.
Logistics for 4P medicine
The accepted limitations in terms of subject-specific pre-
dictive modeling did not preclude other relevant technolo-
gical and organizational outcomes such as the
developments of novel CDSS [42] and the formulation of
the Digital Health Framework (DHF) [50]. We believe that
the deployment of these tools within an integrated care
scenario paves the way toward predictive, preventive, par-
ticipatory and personalized (4P) medicine for these
patients preventing fragmentation of care. It is important
to note that the entire DHF [50] still requires a proof-of-
concept validation before considering specific strategies
for its deployment.
The transition toward a novel biomedical research
scenario fostering 4P medicine has two major biomedi-
cal research goals, namely: i) to speed-up the transfer
of biomedical knowledge, including novel therapies,
into healthcare; and. ii) to generate operational feed-
back from healthcare and informal care into biomedi-
cal research. The last step shall generate two main
added values. Firstly, biological knowledge will be
enriched with information on different dimensions of
the patient (adherence profile, frailty, life styles, socio-
economical and environmental factors, etc...) and, sec-
ondly, it will facilitate an iterative process that shall
result in progressive refinement of subject-specific pre-
dictive modeling. In this regard, the interoperability
among the PHF, the Integrated Care Shared Knowl-
edge Platform and the novel biomedical research plat-
form proposed in [50], within the concept of the DHF,
constitutes a major achievement of the project toward
the consolidation of innovative biomedical research
scenario that overcomes current limitations due to
fragmentation of the information.
Conclusions
The systems approach to COPD heterogeneity explored in
the Synergy-COPD project has generated a novel view of
the phenomenon wherein systemic effects of the disease
and co-morbidity clustering, may all have a relevant role
in the COPD patients, independently from pulmonary
events. The interdependence between pulmonary and
extra-pulmonary events was formulated. Moreover, the
chapter assessed specific strategies for implementation of
the system approach into integrated care management for
chronic patients. Finally, the impact of the novel vision
into biomedical research was explored.
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